U-VUE Biomarker Datasheet - IDO1
|Alternative Name:||Indoleamine 2,3-dioxygenase 1|
|Main cell types:||Lymphoid cells|
IDO1, also known as indoleamine 2,3-dioxygenase, is an enzyme that catalyzes the rate-limiting first step in tryptophan catabolism. IDO1 is overexpressed in response to interferon gamma (IFNγ) and causes immunosuppression through breakdown of tryptophan causing inactivation of T cells.
IHC: Anti-IDO1 antibody [EPR20374] staining normal tonsil FFPE tissue (brown). Hematoxylin counterstain in blue.
IHC: Anti-IDO1 antibody conjugate [EPR20374] staining normal tonsil FFPE tissue (brown). Hematoxylin counterstain in blue.
ISP: Anti-IDO1 antibody conjugate [EPR20374] staining normal tonsil FFPE tissue (green). Nuclear counterstain in blue.
- Zhang, Wentao et al. “Overexpression of Indoleamine 2,3-Dioxygenase 1 Promotes Epithelial-Mesenchymal Transition by Activation of the IL-6/STAT3/PD-L1 Pathway in Bladder Cancer.” Translational oncology, vol. 12,3 (2019): 485-492. DOI: 10.1016/j.tranon.2018.11.012
- Wang, Hong et al. “Altered expression of TIM-3, LAG-3, IDO, PD-L1, and CTLA-4 during nimotuzumab therapy correlates with responses and prognosis of oral squamous cell carcinoma patients.” Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology vol. 48,8 (2019): 669-676. DOI: 10.1111/jop.12883
- Liang, Chen et al. “Investigation of indoleamine 2,3-dioxygenase 1 expression in uveal melanoma.” Experimental eye research, vol. 181 (2019): 112-119. DOI: 10.1016/j.exer.2019.01.005
Each lot of antibody conjugate reagent is quality control tested on positive control tissue and reviewed by Ultivue’s Pathology and Biomarker Analytics group to ensure appropriate staining patterns and signal intensity.
This U-VUE Antibody Conjugate is for Research Use Only. Not for Diagnostic purposes.